TY - JOUR
T1 - Molecular biology of neuroendocrine tumors
T2 - From pathways to biomarkers and targets
AU - Capdevila, J.
AU - Meeker, A.
AU - García-Carbonero, R.
AU - Pietras, K.
AU - Astudillo, A.
AU - Casanovas, O.
AU - Scarpa, A.
N1 - Funding Information:
O. Casanovas Laboratori de Recerca Traslacional, InstitutCatalàd’Oncología-IDIBELL, L’Hospitalet, Center affiliated to the Red Temática de Investigación Cooperativa en Cancer (RTICC), Instituto Carlos III, Spanish Ministry of Science and Innovation, Barcelona, Spain e-mail: ocasanovas@iconcologia.net
Funding Information:
R. García-Carbonero Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS) [Universidad de Sevilla, CSIC, HUVR], Center affiliated to the Red Temática de Investigación Cooperativa en Cancer (RTICC), Instituto Carlos III, Spanish Ministry of Science and Innovation, Sevilla, Spain e-mail: rgcarbonero@gmail.com
PY - 2014/3
Y1 - 2014/3
N2 - Neuroendocrine tumors (NETs) represent a heterogeneous group of diseases with varied natural history and prognosis depending upon the organ of origin and grade of aggressiveness. The most widely used biomarker to determine disease burden and monitor response to treatment is chromogranin A (CgA), but it is far from being the optimal predictive and prognostic biomarker in NETs. Biological understanding and derived treatment options for NETs have changed markedly in recent years. Over the last decade, the genomic landscape of these tumors has been extensively investigated. This has resulted in the discovery of mutations and expression anomalies in genes and pathways such as the PI3K/Akt/mTOR, DAXX/ATRX, and MEN1, which are promising predictive and prognostic biomarkers and future candidates for targeted therapies. Additionally, the study of tumor stroma and environment are one of the most promising fields for discovery of potential new targets and biomarkers.
AB - Neuroendocrine tumors (NETs) represent a heterogeneous group of diseases with varied natural history and prognosis depending upon the organ of origin and grade of aggressiveness. The most widely used biomarker to determine disease burden and monitor response to treatment is chromogranin A (CgA), but it is far from being the optimal predictive and prognostic biomarker in NETs. Biological understanding and derived treatment options for NETs have changed markedly in recent years. Over the last decade, the genomic landscape of these tumors has been extensively investigated. This has resulted in the discovery of mutations and expression anomalies in genes and pathways such as the PI3K/Akt/mTOR, DAXX/ATRX, and MEN1, which are promising predictive and prognostic biomarkers and future candidates for targeted therapies. Additionally, the study of tumor stroma and environment are one of the most promising fields for discovery of potential new targets and biomarkers.
KW - Biomarker
KW - Chromogranin A
KW - Neuroendocrine tumors
UR - http://www.scopus.com/inward/record.url?scp=84899941260&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84899941260&partnerID=8YFLogxK
U2 - 10.1007/s10555-013-9468-y
DO - 10.1007/s10555-013-9468-y
M3 - Article
C2 - 24375391
AN - SCOPUS:84899941260
SN - 0167-7659
VL - 33
SP - 345
EP - 351
JO - Cancer and Metastasis Reviews
JF - Cancer and Metastasis Reviews
IS - 1
ER -